Author Details :
Volume : 2, Issue : 1, Year : 2016
Article Page : 33-40
Objectives: To compare the clinical effect and cost effectiveness of half- and full-dosage abatacept in patients aged over 65 years diagnosed with rheumatoid arthritis.
Methods: Sixty-three elderly patients aged > 65 years with rheumatoid with abatacept were enrolled from four hospitals. Disease Activity Score using C-reactive protein (DAS 28-CRP) were evaluated as well as blood, urine, and radiographic analyses before and 52 weeks after abatacept administration.
Results: DAS 28-CRP decreased from 5.1 ± 0.9 to 2.6 ± 1.0 for half-dosage and from 4.6 ± 1.3 to 2.8 ± 0.9 for full-dosage abatacept, but the differences were not significant. Clinical improvement using DAS 28-CRP was similar in patients aged 65-74 years and those aged > 75 years.
Conclusions: Half-dosage abatacept exhibited the same clinical effect and cost effectiveness of full-dosage of abatacept. And age was not a risk factor for ABT treatment.
Key words: Abatacept, Aged, Clinical equivalence, Half-dose, Rheumatoid arthritis
How to cite : Itoh Y, Shimada W, Kamiya M, Saitoh M, Matsuo O, Kikuchi H, Clinical effects of half- and full-dose abatacept are equivalent. IP Int J Orthop Rheumatol 2016;2(1):33-40
Copyright © 2016 by author(s) and IP Int J Orthop Rheumatol. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (creativecommons.org)